多灶性高级别胶质瘤放疗安全性与疗效分析
该回顾性病例系列分析2011年4月至2019年4月在本机构接受常规分割放疗(伴或不伴同步化疗)的20例多灶性高级别胶质瘤患者,评估其安全性和疗效。结果显示中位生存期8个月,中位无进展生存期5个月,尽管照射野较大,常规分割放疗联合同步化疗仍可安全应用。
要点
- 多灶性高级别胶质瘤患者接受常规分割放疗联合同步化疗,中位生存期8个月,中位无进展生存期5个月。
- 尽管PTV较大(中位425.7 cm3,PTV/脑比率中位32.8%),3级及以上毒性可控。
- 3级毒性4例(脑水肿加重3例,新发癫痫1例),4级毒性1例(同步化疗相关发热性中性粒细胞减少)。
核心结论
- 常规分割放疗联合同步化疗在多灶性高级别胶质瘤中可安全应用,尽管照射治疗野较大。
研究设计与样本
- 回顾性分析2011年4月至2019年4月在本机构接受常规分割放疗(伴或不伴同步化疗)的20例多灶性高级别胶质瘤患者。
- 多灶性定义为MRI T1增强序列上至少两个独立的对比增强病灶。
主要发现
- 20例患者中18例为IDH野生型胶质母细胞瘤,1例为IDH野生型弥漫性星形细胞瘤伴胶质母细胞瘤分子特征,1例为IDH野生型间变性星形细胞瘤。
- 放疗前2例接受切除术,18例仅接受立体定向活检。
- 放疗开始时中位年龄61岁(范围42-84岁),所有病例IDH野生型,11例(55%)MGMT启动子甲基化。
- 中位GTV数量为3个,GTV总和的中位体积为26 cm3,PTV中位体积为425.7 cm3,PTV与脑比率中位为32.8%。
- 脑D2%中位为61.5 Gy(范围51.2-62.7),脑V30Gy和V45中位分别为59.9%(范围33-79.7%)和40.7%(范围14.9-64.1%)。
关键数值与推荐
- 处方方案:60 Gy(2 Gy×30)15例,59.4 Gy(1.8 Gy×33)3例,55 Gy(2.2 Gy×25)1例,50 Gy(2.5 Gy×20)1例。
- 同步替莫唑胺化疗16例,同步替莫唑胺/洛莫司汀化疗1例,同步贝伐珠单抗治疗1例。
临床怎么用
- 对于多灶性高级别胶质瘤,可考虑常规分割放疗联合同步化疗,即使照射野较大。
- 治疗决策时应评估MGMT启动子甲基化状态和IDH突变状态。
- 需关注同步化疗相关毒性,如发热性中性粒细胞减少。
局限性
- 回顾性病例系列,样本量小(20例),可能存在选择偏倚。
- 多灶性高级别胶质瘤罕见,结果需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Multifocal manifestation of high-grade glioma is a rare disease with very unfavourable prognosis. The pathogenesis of multifocal glioma and pathophysiological differences to unifocal glioma are not fully understood. The optimal treatment of patients suffering from multifocal high-grade glioma is not defined in the current guidelines, therefore individual case series may be helpful as guidance for clinical decision-making. METHODS: Patients with multifocal high-grade glioma treated with conventionally fractionated radiation therapy (RT) in our institution with or without concomitant chemotherapy between April 2011 and April 2019 were retrospectively analysed. Multifocality was neuroradiologically assessed and defined as at least two independent contrast-enhancing foci in the MRI T1 contrast-enhanced sequence. IDH mutational status and MGMT methylation status were assessed from histopathology records. GTV, PTV as well as the V30Gy, V45Gy and D2% volumes of the brain were analysed. Overall and progression-free survival were calculated from the diagnosis until death and from start of radiation therapy until diagnosis of progression of disease in MRI for all patients. RESULTS: 20 multifocal glioma cases (18 IDH wild-type glioblastoma cases, one diffuse astrocytic glioma, IDH wild-type case with molecular features of glioblastoma and one anaplastic astrocytoma, IDH wild-type case) were included into the analysis. Resection was performed in two cases and stereotactic biopsy only in 18 cases before the start of radiation therapy. At the start of radiation therapy patients were 61 years old in median (range 42-84 years). Histopathological examination showed IDH wild-type in all cases and MGMT promotor methylation in 11 cases (55%). Prescription schedules were 60 Gy (2 Gy × 30), 59.4 Gy (1.8 Gy × 33), 55 Gy (2.2 Gy × 25) and 50 Gy (2.5 Gy × 20) in 15, three, one and one cases, respectively. Concomitant temozolomide chemotherapy was applied in 16 cases, combined temozolomide/lomustine chemotherapy was applied in one case and concomitant bevacizumab therapy in one case. Median number of GTVs was three. Median volume of the sum of the GTVs was 26 cm3. Median volume of the PTV was 425.7 cm3 and median PTV to brain ratio 32.8 percent. Median D2% of the brain was 61.5 Gy (range 51.2-62.7) and median V30Gy and V45 of the brain were 59.9 percent (range 33-79.7) and 40.7 percent (range 14.9-64.1), respectively. Median survival was eight months (95% KI 3.6-12.4 months) and median progression free survival after initiation of RT five months (95% CI 2.8-7.2 months). Grade 2 toxicities were detected in eight cases and grade 3 toxicities in four cases consisting of increasing edema in three cases and one new-onset seizure. One grade 4 toxicity was detected, which was febrile neutropenia related to concomitant chemotherapy. CONCLUSION: Conventionally fractionated RT with concomitant chemotherapy could safely be applied in multifocal high-grade glioma in this case series despite large irradiation treatment fields.
引用
- Fleischmann DF, Schön R, Corradini S, et al. Multifocal high-grade glioma radiotherapy safety and efficacy. Radiat Oncol. 2021. PMID: 34454558. doi:10.1186/s13014-021-01886-3
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。